Combination of a PI3K-inhibitor with an androgen receptor antagonist

US11185549B2 · kind B2 · utility

Assignees

• Bayer Consumer Care AG · CH
• Bayer Pharma Aktiengesellschaft · DE

Inventor

• Bernard Haendler · Berlin, DE

Key dates

• Filing date: Jun 21, 2018
• Grant date: Nov 30, 2021
• Expiry date: Aug 10, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to: • combinations of: * a component A: which is a PI3K kinase inhibitor, such as copanlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same, for example; * a component B: which is an androgen receptor antagonist, such as darolutamide or enzalutamide for example; and, optionally, * one or more pharmaceutical agents C; in which optionally either or both of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially; • use of such combinations: * in the treatment or prophylaxis of a cancer, particularly prostate cancer, or * for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly prostate cancer; • methods of treatment or prophylaxis of a cancer, particularly prostate cancer, in a subject, comprising administering to said subject a therapeutically effective amount of such a combination; • compositions containing such a combination, together with pharmaceutically acceptable ingredients; and • kits compr…